Methylation Status of the Telomerase Reverse Transcriptase Promoter in Parotid Tumours and Adjacent Parotid Gland Tissue: A Pilot Study on the Implications for Recurrence and Development of Malignancy
- PMID: 40558255
- PMCID: PMC12191565
- DOI: 10.3390/curroncol32060312
Methylation Status of the Telomerase Reverse Transcriptase Promoter in Parotid Tumours and Adjacent Parotid Gland Tissue: A Pilot Study on the Implications for Recurrence and Development of Malignancy
Abstract
Background/objectives: The methylation of the hypermethylated oncological region (THOR) of human telomerase reverse transcriptase (hTERT) may forecast tumour aggressiveness. This pilot study aimed to evaluate THOR methylation as a potential biomarker for recurrence/malignant transformation in salivary gland pleomorphic adenomas (PA).
Methods: THOR methylation was assessed by quantitative pyrosequencing in 96 parotid tissue samples (benign and malignant), including non-neoplastic parotid tissue, PA, recurrent PA (rPA), and carcinomas, along with their adjacent tissues. TERT promoter mutations (TPMs) were analysed by Sanger sequencing.
Results: THOR methylation significantly differed across the seven groups. Malignant tissues showed higher THOR methylation than non-neoplastic tissues, whereas benign tumours showed no significant difference from non-neoplastic tissue. THOR methylation in rPA was closer to carcinoma than to normal tissue, similar in rPA and tissues adjacent to rPA, and higher in tissues adjacent to carcinomas than in non-neoplastic tissues. A subset of PA-adjacent tissues showed epigenetic alterations, suggesting an increased risk of recurrence or malignant transformation (5-15%). No TPMs were detected.
Conclusions: THOR methylation may add information to differentiate normal from carcinogenic tissues and, as such, may be included in a biomarkers panel. Epigenetic alterations in PA-adjacent tissues with normal histology highlight the need for improved diagnostic markers.
Keywords: THOR; biomarkers; cancer; hTERT; methylation; pleomorphic adenoma; salivary gland neoplasms.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures



Similar articles
-
Prediction of High-risk Capsule Characteristics for Recurrence of Pleomorphic Adenoma in the Parotid Gland Based on Habitat Imaging and Peritumoral Radiomics: A Two-center Study.Acad Radiol. 2025 Jul;32(7):4134-4145. doi: 10.1016/j.acra.2025.01.030. Epub 2025 Feb 10. Acad Radiol. 2025. PMID: 39934078
-
Intraoperative frozen section analysis for the diagnosis of early stage ovarian cancer in suspicious pelvic masses.Cochrane Database Syst Rev. 2016 Mar 1;3(3):CD010360. doi: 10.1002/14651858.CD010360.pub2. Cochrane Database Syst Rev. 2016. PMID: 26930463 Free PMC article.
-
Epigenetic silencing of the tumor suppressor TIMP-3 gene in upstream CpG islands in thyroid neoplasms: a cross-sectional study with systematic review.Mol Biol Rep. 2025 Jul 1;52(1):665. doi: 10.1007/s11033-025-10721-x. Mol Biol Rep. 2025. PMID: 40593331
-
Surgical treatment of pleomorphic adenoma of parotid gland in children: a systematic review.Auris Nasus Larynx. 2022 Aug;49(4):547-553. doi: 10.1016/j.anl.2022.01.013. Epub 2022 Jan 31. Auris Nasus Larynx. 2022. PMID: 35101285
-
Dietary fibre for the prevention of recurrent colorectal adenomas and carcinomas.Cochrane Database Syst Rev. 2017 Jan 8;1(1):CD003430. doi: 10.1002/14651858.CD003430.pub2. Cochrane Database Syst Rev. 2017. PMID: 28064440 Free PMC article.
References
-
- Castelo-Branco P., Choufani S., Mack S., Gallagher D., Zhang C., Lipman T., Lipman T., Zhukova N., Walker E.J., Martin D., et al. Differentially methylated region of the TERT promoter and risk for stratification of childhood brain tumours: An integrative genomic and molecular study. Lancet Oncol. 2013;14:534–542. doi: 10.1016/S1470-2045(13)70110-4. - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources